Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Coronary Disease in Diabetes: Diabetic Patients Have Much Greater Plaque Progression

Patients with diabetes mellitus experience significantly greater plaque progression, particularly regarding adverse plaque. Male sex and baseline plaque volume >75% were identified as independent risk factors for plaque progression; the latter actually tripled the risk.

This study with tomographic follow-up sought to determine the rate and extent of plaque progression, changes in plaque features, and clinical predictors of plaque progression in patients with diabetes.

 

A total of 1602 patients (age 61.3 ± 9.0 years; 60.3% men) assessed with coronary computed tomography angiography over a period of at least 24 months were enrolled in the PARADIGM (Progression of Atherosclerotic Plaque Determined by Computed Tomographic Angiography Imaging) trial.


Read also: Silent Diabetes Is the New Stealthy Enemy.


Study endpoints were changes in plaque features and plaque progression in diabetic patients compared with non-diabetic patients, as assessed by serial coronary computed tomography angiography. Plaque progression was defined as any plaque volume increase between baseline and follow-up.

 

As expected, diabetes was a risk factor for plaque progression (odds ratio [OR]: 1.526; 95% confidence interval [CI]: 1.100 to 2.118; p = 0.011). Changes in plaque volume and necrotic core volume were significantly greater in patients with diabetes.

 

Spotty calcification in nodules, positive remodeling, and burden of low-attenuation (soft) plaque were also more frequent in diabetic patients.


Read also: Does a Combination of Diabetes and Acute Coronary Syndrome Change the Revascularization Strategy?


Independent risk factors for plaque progression in patients with diabetes were male sex (OR: 1.4; p = 0.048) and plaque volume at baseline above 75% (OR: 3.1; p = 0.001).

 

The PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) study, published in the 2011 New England Journal of Medicine (NEJM) article A Prospective Natural-History Study of Coronary Atherosclerosis, had included patients with acute coronary syndromes and, after treating the culprit artery, assessed all vessels through intravascular ultrasound (IVUS), looking for clues that might predict which non-culprit vessel plaque might trigger future events. Results were similar in aspects such as plaque volume; however, PROSPECT researchers highlighted a combination of characteristics (plaque volume plus thin-cap fibroatheromas plus minimal luminal area >4.0 mm2).

 

We still have not found the correct risk characteristics so as to apply prophylaxis to functionally non-significant plaque, but clues abound.

 

Conclusion

Diabetic patients experience much greater plaque progression, which is particularly significant as regards adverse plaque. Male sex and, fundamentally, baseline plaque volume >75% were independent predictors of progression.

 

Original title: Natural History of Diabetic Coronary Atherosclerosis by Quantitative Measurement of Serial Coronary Computed Tomographic Angiography Results of the PARADIGM Study (Progression of Atherosclerotic Plaque Determined by Computed Tomographic Angiography Imaging).

Reference: Ung Kim et al. J Am Coll Cardiol Img 2018; online before print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...